Researchers from Taif and Umm Al-Qura universities say limiting coverage to patients with a related condition would cut the public bill to SAR 10.96 billion.
Recap by typeshit. Full story at BIOENGINEER.
About half of Australia's roughly 500,000 GLP-1 users pay privately, A$200 to $700 a month, and the authors argue cost hits those with the most obesity hardest.
Ireland's drug pricing body recommended semaglutide over tirzepatide for cost reasons, and Higgins says it's the right call, with a pun he didn't get to use.
Researchers tracked 8,914 insured patients in JAMA Health Forum. Above $75 out of pocket, nonadherence topped 80%, says author Eunhae Shin.
Costco is adding Novo Nordisk's semaglutide shots to what it offers. Details are thin here, so tap through for how pricing and access will work.
CEO J. David Warren, who did early research on elamipretide, says the company will target metabolic health and muscle preservation. It's also weighing GLP-1 companion products.
An explainer on how GLP-1s lower blood sugar by prompting insulin release, cutting glucose output from the liver and slowing how fast the stomach empties.
Loading…